Decade Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Decade Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-59,730	Closed	-$1.45M	–	152
2014 Q1	$1.45M	Buy	+59,730	New	+$1.51M	0.1%	132

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Decade Capital Management's ACAD Position: Q2 2014 in Review

Decade Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2014, closing a stake of 59,730 shares — an estimated $1.45M sold.

Decade Capital Management first reported a position in ACAD in Q1 2014 and held it in 1 quarter. The position peaked at $1.45M in Q1 2014. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

Decade Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Decade Capital Management sold 59,730 Acadia Pharmaceuticals shares in Q2 2014, an estimated $1.45M.
Decade Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 1 quarter.
Decade Capital Management's Acadia Pharmaceuticals position peaked at $1.45M in Q1 2014.
160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on Decade Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.